Alpha Lipoic Acid Solution Stabilization via pH and Polyol Solvent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Alpha lipoic acid has low bioavailability and stability issues when administered orally due to its low solubility in water and rapid degradation in acidic environments, leading to reduced effectiveness in treating conditions like diabetic neuropathy.
Innovation Solution
A pharmaceutical solution with a pH of 7.0 to 9.5, comprising alpha lipoic acid or its enantiomer, an inorganic compound, and a solvent mixture of water and polyol (such as propylene glycol), which stabilizes alpha lipoic acid, enhances bioavailability, and improves tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If alpha lipoic acid is administered orally in conventional formulations, then it can be given by simple oral route, but it exhibits low bioavailability and rapid degradation due to low solubility in water and instability in acidic environments
Solution Approach 1:
The patent changes the pH parameter of the solution to alkaline range (7.0-9.5) to prevent degradation of alpha lipoic acid. This parameter change resolves the contradiction by creating a stable environment that maintains high bioavailability while preserving the ease of oral administration route.
Solution Approach 2:
The patent uses a composite solvent system combining water with polyols (propylene glycol, glycerol, polyethylene glycol, or polypropylene glycol) in specific ratios. This composite material approach improves solubility and stability of alpha lipoic acid, thereby enhancing bioavailability while maintaining oral administrability.
2Ease of operation
If alpha lipoic acid is dissolved in water for oral solution, then it improves edibility and absorption, but it degrades rapidly due to low stability in aqueous acidic environments
Solution Approach 1:
The patent raises the pH parameter from acidic to alkaline range (7.0-9.5), which fundamentally changes the stability profile of alpha lipoic acid in aqueous solution. This parameter change allows the formulation to maintain both edibility (through oral administration) and high stability over time.
Solution Approach 2:
The patent introduces polyols as intermediary substances that mediate between water and alpha lipoic acid. These polyols enhance solubility and provide additional stability protection, allowing the formulation to achieve both good edibility and high compositional stability.
3Ease of manufacture
If conventional formulations are used, then manufacturing is simple, but the pharmacokinetic profile shows reduced effectiveness and unpleasant odors and flavors
Solution Approach 1:
The patent modifies the pH parameter to alkaline range and specifies particular polyol concentrations, which improves therapeutic efficacy through enhanced stability and bioavailability. The manufacturing process remains relatively simple, requiring only dissolution and pH adjustment, thus maintaining ease of manufacture while significantly improving reliability.
4Reliability
If alpha lipoic acid is stabilized in solution, then it improves bioavailability and reduces degradation, but it requires specific pH control and polyol additives
Solution Approach 1:
The patent establishes specific pH range (7.0-9.5) and polyol concentration parameters that optimize bioavailability. While these parameter specifications add some formulation complexity, they ensure high reliability and consistent performance. The complexity is managed through clear parameter definitions rather than complex processing steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution maintains alpha lipoic acid stability and bioavailability, reducing unpleasant odors and flavors, and significantly increases blood concentration peaks, demonstrating improved pharmacokinetic profiles and therapeutic efficacy.
Implementation Method 1
having a pH 7.0 to 9.5, and comprising alpha-lipoic acid or its enantiomer, an inorganic compound selected from hydroxide, carbonate, bicarbonate and mixtures thereof
Implementation Method 2
a solvent, said solvent being a mixture of water and a polyol selected from propylene glycol, glycerol, polyethylene glycol, polypropylene glycol, and mixtures thereof
Data Source
Figure 1
AI summary
A solution is disclosed having a pH 7.0 to 9.5, comprising alpha lipoic acid or its enantiomer, an inorganic compound and a solvent, said solvent being a mixture of water and a polyol. Said solution presents high stability of the alpha lipoic acid over time, as well as high edibility and bioavailability.